Clinical trials: Relapsed
Relapsed/Refractory Marginal Zone Lymphoma (MZL)
Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL
- Trial name
- NCT07896590
- Testing
- Orelabrutinib, ICP-248
- Where
- 46 sites in China
- Volunteers
- 292 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Acute Myeloid Leukemia (AML), Relapsed/Refractory Acute Myeloid Leukemia
CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an autologous CLL-1/CD70 dual-target CAR-T cell…
- Trial name
- NCT07897136
- Testing
- CLL-1-CD70 CAR-T Cell Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
Acute Leukemia, Relapsed or Refractory Pediatric Leukemia
Menin Inhibitors in Pediatric Relapsed or Refractory Acute Leukemia
Acute leukemia is the most common childhood cancer. Despite advances in targeted therapies and immunotherapies, treatment remains challenging for children with relapsed or refractory acute leukemia, particularly those with KMT2A…
- Conditions
- Acute Leukemia, Relapsed or Refractory Pediatric Leukemia, KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated Leukemia, Menin Inhibitor Treatment
- Trial name
- MENIN-PED (NCT07898436)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal…
- Trial name
- NCT04973605
- Testing
- Sonrotoclax, Dexamethasone, Carfilzomib
- Where
- 74 sites in United States, Australia and 11 more
- Volunteers
- 246 people
- Sponsor
- BeOne Medicines
TCR-T Cells, Refractory Solid Tumors
KSX01-TCRT Injection Project in Solid Tumors
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
- Conditions
- TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
- Trial name
- NCT05811975
- Testing
- KSX01-TCRT injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Relapsed or Refractory Large B-cell Lymphoma
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy.
- Trial name
- NCT07479797
- Testing
- KITE-753, Axicabtagene Ciloleucel, Fludarabine
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 550 people
- Sponsor
- Kite, A Gilead Company
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM).
- Trial name
- Prime REMIX (NCT07725406)
- Testing
- Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer
- Trial name
- NCT07770698
- Testing
- sonrotoclax, Azacitidine, Inotuzumab ozogamicin
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.
- Trial name
- NCT03618550
- Testing
- pembrolizumab, gemcitabine, vinorelbine
- Where
- 10 sites in United States
- Volunteers
- 257 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
TCR-T Cells, Refractory Solid Tumors
KSH01-TCRT Solid Tumors
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
- Conditions
- TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
- Trial name
- KSH01-TCRT (NCT05539833)
- Testing
- KSH01 injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- TCRx Therapeutics Co.Ltd
Relapsed/Refractory Non-Hodgkin Lymphoma
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6…
- Trial name
- NCT06090539
- Testing
- BMS-986458, Rituximab, Glofitamab/Obinutuzumab
- Where
- 76 sites in United States, Chile and 13 more
- Volunteers
- 460 people
- Sponsor
- Bristol-Myers Squibb
Relapsed and/or Refractory Multiple Myeloma
Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex
This is a Phase 1/2, multi-centre, single-arm, open-label, dose-escalation study that will evaluate the safety and efficacy of IV GSK2857916 in combination with PO pomalidomide and low-dose PO dexamethasone in subjects with…
- Trial name
- NCT03715478
- Testing
- GSK2857916 with Pomalidomide and Dexamethasone
- Where
- 9 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Canadian Myeloma Research Group
NHL, NHL, Relapsed, Adult
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
- Trial name
- NCT05879744
- Testing
- CLN-978
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cullinan Therapeutics Inc.
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
This is a research study to find out if adding a new study drug called revumenib to commonly used chemotherapy drugs is safe and if they have beneficial effects in treating patients with acute myeloid leukemia (AML) or acute…
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
- Trial name
- NCT06177067
- Testing
- Revumenib, Venetoclax, Azacitidine
- Where
- 10 sites in United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Lymphoma, B-cell Lymphomas
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
The goal of this clinical trial is to assess the clinical efficacy of bridging therapy with glofitamab/gemcitabine/oxaliplatin (Glofit-GemOx) followed by lisocabtagene maraleucel (liso-cel) in relapsed/refractory large B-cell…
- Conditions
- Lymphoma, B-cell Lymphomas, Relapsed/Refractory Large B-cell Lymphoma, Large B-cell Lymphoma
- Trial name
- GLORY (NCT07711483)
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Massachusetts General Hospital
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study
This is a Phase I/II study to evaluate the safety and efficacy of autologous T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 in adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic…
- Trial name
- CARLLA-B1 (NCT07890025)
- Testing
- MB-CART19.1
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Lymphoma, Relapsed
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma.
- Conditions
- Lymphoma, Relapsed, Refractory
- Trial name
- NCT03179930
- Testing
- Entinostat, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Primary Central Nervous System Lymphoma, Recurrent Cancer
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL).
- Conditions
- Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
- Trial name
- NCT04421560
- Testing
- Ibrutinib, Pembrolizumab, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Small Cell Lung Cancer
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of…
- Trial name
- NCT05153239
- Testing
- Irinotecan, Lurbinectedin, Topotecan
- Where
- 210 sites in United States, Australia and 22 more
- Volunteers
- 705 people
- Sponsor
- PharmaMar